ESMO 2026持续更新

atirmociclib

8 篇报道2 个报道来源20 小时前更新

先了解这件事

报道摘要

辉瑞启动atirmociclib联合giredestrant治疗乳腺癌的FOURLIGHT-4 III期临床试验（NCT07890597）。研究计划入组3800例ER阳性、HER2阴性早期乳腺癌中高复发风险成人患者，比较atirmociclib联合方案与giredestrant单药辅助治疗；atirmociclib为CDK4小分子抑制剂。

摘自中文产业新闻

报道时间线

沿着报道，了解事件的不同侧面。

10月24日

15:49
ESMO 2026 现场信号
Very promising randomized results with the CDK4 selective inhibitor atirmociclib presented by @antgiorda. Next gen CDKs are here! #ESMO26 #ESMOAmbassadors
15:11
ESMO 2026 现场信号
Results with $PFE's CDK4i atirmociclib at #ESMO26...in 2L breast cancer, a use that's no longer a focus (focus now on 1L). One treatment-related death with atirmo, from pneumonitis
15:10
ESMO 2026 现场信号
Selective CDK4 inhibition in endocrine-resistant #BreastCancer: phase 2 results for atirmociclib + fulvestrant, an Oral Abstract Session at #ESMO26 @OncoAlert @Larvol
15:07
ESMO 2026 现场信号
#FOURLIGHT1 CDK4 atirmociclib
15:06
ESMO 2026 现场信号
Oral abstract #BreastCancer session at #ESMO26: phase 2 results with the #CDK4 inhibitor #atirmociclib in addition to #fulvestrant presented by the great @antgiorda 🇮🇹 in patients
15:06
ESMO 2026 现场信号
FourLight shows 1st CDK4i Atirmociclib after CDK4/6i shows significant improvement in mPFS 9.4 vs 6.6 mos HR=0.60

10月23日

21:40
ESMO 2026 现场信号
Join Dr. Antonio Giordano (@antgiorda) at #ESMO26 for Proffered Paper Session 2, featuring data on the efficacy and safety of atirmociclib + fulvestrant in patients with HR+/HER2–
06:01
中文产业新闻
10月魔方TOP药企动态播报｜辉瑞atirmociclib启动一项针对乳腺癌的III期临床试验
辉瑞启动atirmociclib联合giredestrant治疗乳腺癌的FOURLIGHT-4 III期临床试验（NCT07890597）。研究计划入组3800例ER阳性、HER2阴性早期乳腺癌中高复发风险成人患者，比较atirmociclib联合方案与giredestrant单药辅助治疗；atirmociclib为CDK4小分子抑制剂。

本事件热度走势

当前热度 40·可比范围峰值 68（10月24日 16:00）·近 24 小时可比范围变化 +256%·当前参与者 8

参与者计数8

热度走势

上图是参与者计数，下图是热度。趋势仅比较持续完整观测到的相同主体，范围可能小于当前热度统计。移动指针或点击图表查看每小时读数；键盘可用左右方向键切换。